Guo Mengqi, Xia Zongyi, Hong Yefeng, Ji Hongwei, Li Fuhai, Liu Wenheng, Li Shaohua, Xin Hui, Tan Kai, Lian Zhexun
Department of Cardiology, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266003, Shandong, China.
J Inflamm (Lond). 2023 Nov 1;20(1):35. doi: 10.1186/s12950-023-00357-8.
Diabetes mellitus is one of the causes of poor ventricular remodelling and poor cardiac recovery after myocardial infarction (MI). We previously reported that tissue factor pathway inhibitor-2 (TFPI2) was downregulated in response to hyperglycaemia and that it played a pivotal role in extracellular matrix (ECM) degradation and cell migration. Nonetheless, the function and mechanism of TFPI2 in post-MI remodelling under diabetic conditions remain unclear. Therefore, in the present study, we investigated the role of TFPI2 in post-MI effects in a diabetic mouse model.
TFPI2 expression was markedly decreased in the infarcted myocardium of diabetic MI mice compared with that in non-diabetic mice. TFPI2 knockdown in the MI mouse model promoted fibroblast activation and migration as well as matrix metalloproteinase (MMP) expression, leading to disproportionate fibrosis remodelling and poor cardiac recovery. TFPI2 silencing promoted pro-inflammatory M1 macrophage polarization, which is consistent with the results of TFPI2 downregulation and M1 polarization under diabetic conditions. In contrast, TFPI2 overexpression in diabetic MI mice protected against adverse cardiac remodelling and functional deterioration. TFPI2 overexpression also inhibited MMP2 and MMP9 expression and attenuated fibroblast activation and migration, as well as excessive collagen production, in the infarcted myocardium of diabetic mice. TFPI2 promoted an earlier phenotype transition of pro-inflammatory M1 macrophages to reparative M2 macrophages via activation of peroxisome proliferator-activated receptor gamma.
This study highlights TFPI2 as a promising therapeutic target for early resolution of post-MI inflammation and disproportionate ECM remodelling under diabetic conditions.
糖尿病是心肌梗死(MI)后心室重构不良和心脏恢复不佳的原因之一。我们之前报道过,组织因子途径抑制剂-2(TFPI2)在高血糖反应中表达下调,且在细胞外基质(ECM)降解和细胞迁移中起关键作用。然而,糖尿病条件下TFPI2在心肌梗死后重构中的功能和机制仍不清楚。因此,在本研究中,我们在糖尿病小鼠模型中研究了TFPI2在心肌梗死后效应中的作用。
与非糖尿病小鼠相比,糖尿病心肌梗死小鼠梗死心肌中的TFPI2表达明显降低。在心肌梗死小鼠模型中敲低TFPI2会促进成纤维细胞活化和迁移以及基质金属蛋白酶(MMP)表达,导致不成比例的纤维化重构和心脏恢复不佳。TFPI2沉默促进促炎性M1巨噬细胞极化,这与糖尿病条件下TFPI2下调和M1极化的结果一致。相反,糖尿病心肌梗死小鼠中TFPI2过表达可防止不良心脏重构和功能恶化。TFPI2过表达还抑制糖尿病小鼠梗死心肌中MMP2和MMP9的表达,并减弱成纤维细胞活化和迁移以及过量胶原蛋白的产生。TFPI2通过激活过氧化物酶体增殖物激活受体γ促进促炎性M1巨噬细胞向修复性M2巨噬细胞的早期表型转变。
本研究强调TFPI2是糖尿病条件下早期解决心肌梗死后炎症和不成比例的ECM重构的有前景的治疗靶点。